Mustang Bio Inc Net Income per Employee (MBIO), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Mustang Bio inc   (NASDAQ: MBIO)
 

Mustang Bio Inc Net Income per Employee

MBIO's Quarterly Results, Trends, Rankings, Statistics
Mustang Bio Inc recorded a cumulative net loss of $-3 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 171 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 3610, from total ranking in previous quarter at 4084.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MBIO Net Income per Employee (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -758,250 -680,750 -480,250 -583,750 -819,250
MBIO's Total Ranking # 3610 # 4084 # 3716 # 3910 # 4368
Seq. Net Income Change - - - - -

MBIO Company Profile >> Back to MBIO Efficiency Comparisons >> Compare MBIO Net Income per Employee to its Competitors

MBIO Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 172
Healthcare Sector # 511
Overall Market # 3610

Net Income per Employee Statistics
High Average Low
$ -480,250 $ -10,260,901 $ -19,485,000
(Dec 31 2025)   (Sep 30 2022)




  News about Mustang Bio inc Income per employee

Mustang Bios Promising Advances in CAR T-Cell Therapy Amid Financial Challenges

Mustang Bio Inc. recently received Orphan Drug Designation from the U.S. FDA for its innovative MB-101 therapy, which utilizes IL13Ra2-targeted CAR T-cells to combat astrocytomas and glioblastomas. This reflects significant progress in the field of oncology, highlighting the potential of personalized medicine. However, the company faces substantial financial hurdles, evidenced by a net loss of $70 million over the past year, raising questions about its sustainability in a competitive pharmaceutical landscape where other companies are achieving higher productivity and profits. The development of CAR T-cell therapies has transformed the treatment landscape for various cancers, particularly those that are notoriously challenging to manage, such as glioblastomas and astrocytomas. Mustang Bio s recent achievement in securing Orphan Drug Designation for MB-101 marks a significant milestone in the search for effective therapies for these aggressive tumors. Despite the promising results from ongoing clinical trials, financial viability remains a critical concern for the company.




Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2026Number of Employees Jun 30 2026


Date modified: 2026-09-12T18:41:09+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.